Gastrointestinal Sistem Sorunları

Bacon CG, Giovannucci E, Testa M, Glass TA, Kawachi I: The association of treatment‐related symptoms with quality‐of‐life outcomes for localized prostate carcinoma patients. Cancer 2002, 94(3):862-871.

Hardy J, Davis MP: The management of nausea and vomiting not related to anticancer therapy in patients with cancer. Current Treatment Options in Oncology 2021, 22:1-14.

Herrstedt J, Clark-Snow R, Ruhlmann C, Molassiotis A, Olver I, Rapoport BL, Aapro M, Dennis K, Hesketh P, Navari R: 2023 MASCC and ESMO guideline update for the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting. ESMO open 2024, 9(2):102195.

Tradounsky GE: Gastro-Intestinal Symptoms in Palliative Care Patients. Current Oncology 2024, 31(4):2341-2352.

Holt DW, Volans GN: Gastrointestinal symptoms of digoxin toxicity. British Medical Journal 1977, 2(6088):704.

Hwang W-J, Tsai J-J: Acute phenytoin intoxication: causes, symptoms, misdiagnoses, and outcomes. The Kaohsiung journal of medical sciences 2004, 20(12):580-585.

Murray-Brown F, Dorman S: Haloperidol for the treatment of nausea and vomiting in palliative care patients. Cochrane Database of Systematic Reviews 2015(11).

Davis MP, Hallerberg G, Cancer PMSGotMAoSCi: A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation. Journal of pain and symptom management 2010, 39(4):756-767.

Sykes N: Constipation and diarrhoea. Oxford textbook of palliative medicine 1993, 2:513-526.

Larkin PJ, Sykes N, Centeno C, Ellershaw J, Elsner F, Eugene B, Gootjes J, Nabal M, Noguera A, Ripamonti C: The management of constipation in palliative care: clinical practice recommendations. Palliative medicine 2008, 22(7):796-807.

Staats PS, Markowitz J, Schein J: Incidence of constipation associated with long-acting opioid therapy: a comparative study. Southern medical journal 2004, 97(2):129-135.

Thorpe DM: Management of opioid-induced constipation. Current pain and headache reports 2001, 5:237-240.

Bouras EP, Tangalos EG: Chronic constipation in the elderly. Gastroenterology Clinics 2009, 38(3):463-480.

Genz H, Jenetzky E, Hauer K, Oster P, Pfisterer M-D: Palliative geriatrics: What are the differences between oncologic and non-oncologic palliative geriatric inpatients? Zeitschrift für Gerontologie und Geriatrie 2010, 43:369-375.

Teunissen SC, de Haes HC, Voest EE, de Graeff A: Does age matter in palliative care? Critical reviews in oncology/hematology 2006, 60(2):152-158.

Van Lancker A, Velghe A, Van Hecke A, Verbrugghe M, Van Den Noortgate N, Grypdonck M, Verhaeghe S, Bekkering G, Beeckman D: Prevalence of symptoms in older cancer patients receiving palliative care: a systematic review and meta-analysis. Journal of Pain and Symptom Management 2014, 47(1):90-104.

Laugsand EA, Jakobsen G, Kaasa S, Klepstad P: Inadequate symptom control in advanced cancer patients across Europe. Supportive Care in Cancer 2011, 19:2005-2014.

Dukas L, Willett WC, Giovannucci EL: Association between physical activity, fiber intake, and other lifestyle variables and constipation in a study of women. Official journal of the American College of Gastroenterology| ACG 2003, 98(8):1790-1796.

Winge K, Rasmussen D, Werdelin L: Constipation in neurological diseases. Journal of neurology, neurosurgery, and psychiatry 2003, 74(1):13.

Larkin P, Cherny N, La Carpia D, Guglielmo M, Ostgathe C, Scotté F, Ripamonti C, Committee EG: Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines. Annals of oncology 2018, 29:iv111-iv125.

Pappagallo M: Incidence, prevalence, and management of opioid bowel dysfunction. The American journal of surgery 2001, 182(5):S11-S18.

Meissner W, Leyendecker P, Mueller-Lissner S, Nadstawek J, Hopp M, Ruckes C, Wirz S, Fleischer W, Reimer K: A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. European Journal of Pain 2009, 13(1):56-64.

Holzer P, Ahmedzai SH, Niederle N, Leyendecker P, Hopp M, Bosse B, Spohr I, Reimer K: Opioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its management. Journal of Opioid Management 2009, 5(3):145-151.

Talley NJ: Serotoninergic neuroenteric modulators. The Lancet 2001, 358(9298):2061-2068.

Haim N, Epelbaum R, Ben‐Shahar M, Yarnitsky D, Simri W, Robinson E: Full dose vincristine (without 2‐mg dose limit) in the treatment of lymphomas. Cancer 1994, 73(10):2515-2519.

Hwu W-J, Krown SE, Panageas KS, Menell JH, Chapman PB, Livingston PO, Williams LJ, Quinn CJ, Houghton AN: Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. Journal of clinical oncology 2002, 20(11):2610-2615.

Librach SL, Bouvette M, De Angelis C, Farley J, Oneschuk D, Pereira JL, Syme A, Illness CCDGfCiPwAP: Consensus recommendations for the management of constipation in patients with advanced, progressive illness. Journal of pain and symptom management 2010, 40(5):761-773.

De Giorgio R, Zucco FM, Chiarioni G, Mercadante S, Corazziari ES, Caraceni A, Odetti P, Giusti R, Marinangeli F, Pinto C: Management of opioid-induced constipation and bowel dysfunction: expert opinion of an Italian multidisciplinary panel. Advances in therapy 2021, 38(7):3589-3621.

McCallum P, Walsh D, Nelson KA: Can a soft diet prevent bowel obstruction in advanced pancreatic cancer? Supportive care in cancer 2002, 10:174-175.

Markland AD, Burgio KL, Whitehead WE, Richter HE, Wilcox CM, Redden DT, Beasley TM, Goode PS: Loperamide versus psyllium fiber for treatment of fecal incontinence: the fecal incontinence prescription (Rx) management (FIRM) randomized clinical trial. Diseases of The Colon & Rectum 2015, 58(10):983-993.

Whitehead WE, Drinkwater D, Cheskin LJ, Heller BR, Schuster MM: Constipation in the elderly living at home: definition, prevalence, and relationship to lifestyle and health status. Journal of the American Geriatrics Society 1989, 37(5):423-429.

Star A, Boland JW: Updates in palliative care–recent advancements in the pharmacological management of symptoms. Clinical Medicine 2018, 18(1):11-16.

Jones R, Prommer E, Backstedt D: Naloxegol: a novel therapy in the management of opioid-induced constipation. American Journal of Hospice and Palliative Medicine® 2016, 33(9):875-880.

Dzierżanowski T, Mercadante S: Constipation in cancer patients—an update of clinical evidence. Current Treatment Options in Oncology 2022, 23(7):936-950.

Bossi P, Antonuzzo A, Cherny N, Rosengarten O, Pernot S, Trippa F, Schuler U, Snegovoy A, Jordan K, Ripamonti C: Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. Annals of Oncology 2018, 29:iv126-iv142.

Boussios S, Pentheroudakis G, Katsanos K, Pavlidis N: Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management. Annals of gastroenterology 2012, 25(2):106.

Levy E, Piedbois P, Buyse M, Pignon J, Rougier P, Ryan L, Hansen R, Zee B, Weinerman B, Pater J: Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 1998, 16(11):3537-3541.

Yumuk P, Aydin S, Dane F, Gumus M, Ekenel M, Aliustaoglu M, Karamanoglu A, Sengoz M, Turhal S: The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients. International journal of colorectal disease 2004, 19:609-610.

Van Cutsem E, Findlay M, Osterwalder B, Kocha W, Dalley D, Pazdur R, Cassidy J, Dirix L, Twelves C, Allman D: Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. Journal of Clinical Oncology 2000, 18(6):1337-1345.

Baratelli C, Zichi C, Di Maio M, Brizzi MP, Sonetto C, Scagliotti GV, Tampellini M: A systematic review of the safety profile of the different combinations of fluoropyrimidines and oxaliplatin in the treatment of colorectal cancer patients. Critical Reviews in Oncology/Hematology 2018, 122:21-29.

Pessi M, Zilembo N, Haspinger E, Molino L, Di Cosimo S, Garassino M, Ripamonti C: Targeted therapy-induced diarrhea: a review of the literature. Critical reviews in oncology/hematology 2014, 90(2):165-179.

Naidoo J, Page D, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok J: Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Annals of Oncology 2015, 26(12):2375-2391.

Pernot S, Ramtohul T, Taieb J: Checkpoint inhibitors and gastrointestinal immune-related adverse events. Current opinion in oncology 2016, 28(4):264-268.

Gupta A, De Felice K, Loftus Jr EV, Khanna S: Systematic review: colitis associated with anti‐CTLA‐4 therapy. Alimentary pharmacology & therapeutics 2015, 42(4):406-417.

Postow MA: Managing immune checkpoint-blocking antibody side effects. American Society of Clinical Oncology Educational Book 2015, 35(1):76-83.

Som A, Mandaliya R, Alsaadi D, Farshidpour M, Charabaty A, Malhotra N, Mattar MC: Immune checkpoint inhibitor-induced colitis: a comprehensive review. World journal of clinical cases 2019, 7(4):405.

Hodi FS, O'day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC: Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine 2010, 363(8):711-723.

Ibrahim R, Berman D, DePril V, Humphrey R, Chen T, Messina M, Chin K, Liu H, Bielefield M, Hoos A: Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma. Journal of Clinical Oncology 2011, 29(15_suppl):8583-8583.

De Velasco G, Je Y, Bossé D, Awad MM, Ott PA, Moreira RB, Schutz F, Bellmunt J, Sonpavde GP, Hodi FS: Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. Cancer immunology research 2017, 5(4):312-318.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New England journal of medicine 2015, 373(1):23-34.

Marthey L, Mateus C, Mussini C, Nachury M, Nancey S, Grange F, Zallot C, Peyrin-Biroulet L, Rahier J-F, Bourdier de Beauregard M: Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. Journal of Crohn's and Colitis 2016, 10(4):395-401.

Verschuren EC, van den Eertwegh AJ, Wonders J, Slangen RM, van Delft F, van Bodegraven A, Neefjes-Borst A, de Boer NK: Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis. Clinical Gastroenterology and Hepatology 2016, 14(6):836-842.

O’Connor A, Marples M, Mulatero C, Hamlin J, Ford AC: Ipilimumab-induced colitis: experience from a tertiary referral center. Therapeutic Advances in Gastroenterology 2016, 9(4):457-462.

Heinzerling L, Goldinger SM: A review of serious adverse effects under treatment with checkpoint inhibitors. Current opinion in oncology 2017, 29(2):136-144.

Shivaji UN, Jeffery L, Gui X, Smith SC, Ahmad OF, Akbar A, Ghosh S, Iacucci M: Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management. Therapeutic advances in gastroenterology 2019, 12:1756284819884196.

Horvat TZ, Adel NG, Dang T-O, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D'Angelo SP, Woo KM: Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. Journal of Clinical Oncology 2015, 33(28):3193-3198.

Bergqvist V, Hertervig E, Gedeon P, Kopljar M, Griph H, Kinhult S, Carneiro A, Marsal J: Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunology, Immunotherapy 2017, 66:581-592.

Andreyev HJN, Wotherspoon A, Denham JW, Hauer-Jensen M: “Pelvic radiation disease”: new understanding and new solutions for a new disease in the era of cancer survivorship. Scandinavian journal of gastroenterology 2011, 46(4):389-397.

Harb AH, Abou Fadel C, Sharara AI: Radiation enteritis. Current gastroenterology reports 2014, 16:1-9.

Fernández-Bañares F, Villá S, Esteve M, Roca M, Cabré E, Abad-Lacruz A, Martín-Comín J, Gassull MA: Acute effects of abdominopelvic irradiation on the orocecal transit time: its relation to clinical symptoms, and bile salt and lactose malabsorption. American Journal of Gastroenterology (Springer Nature) 1991, 86(12).

Liu M-M, Li S-T, Shu Y, Zhan H-Q: Probiotics for prevention of radiation-induced diarrhea: A meta-analysis of randomized controlled trials. PloS one 2017, 12(6):e0178870.

Nightingale J, Woodward JM: Guidelines for management of patients with a short bowel. Gut 2006, 55(suppl 4):iv1-iv12.

Wallace A, Phillips-Clarke C, Peiris S, Thiruppathy K: Cancer management from a chronic gastrointestinal function perspective. Clinical Medicine 2023, 23(6):545-548.

Fernandes DC, Andreyev HJN: Chronic diarrhoea in an oncology patient–Clinical assessment and decision making. Best Practice & Research Clinical Gastroenterology 2020, 48:101708.

Liu J, Liu C, Yue J: Radiotherapy and the gut microbiome: facts and fiction. Radiation Oncology 2021, 16(1):9.

Muls AC: Gastrointestinal consequences of cancer treatment and the wider context: A bad gut feeling. Acta oncologica 2014, 53(3):297-306.

Davila ML: Neutropenic enterocolitis. Current treatment options in gastroenterology 2006, 9(3):249-255.

Andreyev HJN, Davidson SE, Gillespie C, Allum WH, Swarbrick E: Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer. Gut 2012, 61(2):179-192.

Health UDo, Services H: National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 5.0. 2017. Online at https://ctep cancer gov/protocolDevelopment/electronic_applications/ctc htm# ctc_50 There is no corresponding record for this reference 2023.

Andreyev HJN, Benton BE, Lalji A, Norton C, Mohammed K, Gage H, Pennert K, Lindsay JO: Algorithm-based management of patients with gastrointestinal symptoms in patients after pelvic radiation treatment (ORBIT): a randomised controlled trial. The Lancet 2013, 382(9910):2084-2092.

Benton B, Norton C, Lindsay J, Dolan S, Andreyev H: Can nurses manage gastrointestinal symptoms arising from pelvic radiation disease? Clinical oncology 2011, 23(8):538-551.

Andreyev J, Ross P, Donnellan C, Lennan E, Leonard P, Waters C, Wedlake L, Bridgewater J, Glynne-Jones R, Allum W: Guidance on the management of diarrhoea during cancer chemotherapy. The Lancet Oncology 2014, 15(10):e447-e460.

Obita GP, Boland EG, Currow DC, Johnson MJ, Boland JW: Somatostatin analogues compared with placebo and other pharmacologic agents in the management of symptoms of inoperable malignant bowel obstruction: a systematic review. Journal of Pain and Symptom Management 2016, 52(6):901-919. e901.

Shariff F, Bogach J, Guidolin K, Nadler A: Malignant bowel obstruction management over time: are we doing anything new? A current narrative review. Annals of Surgical Oncology 2022:1-11.

Demarest K, Lavu H, Collins E, Batra V: Comprehensive diagnosis and management of malignant bowel obstruction: a review. Journal of Pain & Palliative Care Pharmacotherapy 2023, 37(1):91-105.

Hsu K, Prommer E, Murphy MC, Lankarani‐Fard A: Pharmacologic management of malignant bowel obstruction: when surgery is not an option. Journal of Hospital Medicine 2019, 14(6):367-373.

Ferguson HJM, Ferguson CI, Speakman J, Ismail T: Management of intestinal obstruction in advanced malignancy. Annals of medicine and surgery 2015, 4(3):264-270.

Lambert LA, Wiseman J: Palliative management of peritoneal metastases. Annals of Surgical Oncology 2018, 25:2165-2171.

Yeo CT, Merchant SJ: Considerations in the management of malignant bowel obstruction. Surgical Oncology Clinics 2021, 30(3):461-474.

NCCN: NCCN Guidelines Version 1.2024 Palliative Care. In: National Comprehensive Cancer Network Guidelines, 10/8/2024 Access Date. 2024: MS-21, 22.

Ripamonti C, Guglielmo M: Malignant Bowel Obstruction. ESMO Handbooks: Supportive and Palliative Care European Society for Medical Oncology 2022:73-76.

Feuer DJ, Broadley KE, Cochrane Pain P, Group SC: Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane database of systematic reviews 1996, 2017(6).

Kaneishi K, Kawabata M, Morita T: Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction. Journal of pain and symptom management 2012, 44(4):604-607.

Porzio G, Aielli F, Verna L, Galletti B, Shoja e Razavi G, Ficorella C: Can malignant bowel obstruction in advanced cancer patients be treated at home? Supportive Care in Cancer 2011, 19:431-433.

Mercadante S, Ferrera P, Villari P, Marrazzo A: Aggressive pharmacological treatment for reversing malignant bowel obstruction. Journal of pain and symptom management 2004, 28(4):412-416.

Zelek L, Laval G, Asselain B: Somatostatin analogs for malignant bowel obstruction resulting from peritoneal carcinomatosis. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2013, 31(19):2519-2520.

Mercadante S, Casuccio A, Mangione S: Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review. Journal of pain and symptom management 2007, 33(2):217-223.

Mercadante S, Porzio G: Octreotide for malignant bowel obstruction: twenty years after. Critical reviews in oncology/hematology 2012, 83(3):388-392.

Dittrich A, Schubert B, Kramer M, Lenz F, Kast K, Schuler U, Schuler MK: Benefits and risks of a percutaneous endoscopic gastrostomy (PEG) for decompression in patients with malignant gastrointestinal obstruction. Supportive Care in Cancer 2017, 25(9):2849-2856.

Chen Y-I, Itoi T, Baron TH, Nieto J, Haito-Chavez Y, Grimm IS, Ismail A, Ngamruenphong S, Bukhari M, Hajiyeva G et al: EUS-guided gastroenterostomy is comparable to enteral stenting with fewer re-interventions in malignant gastric outlet obstruction. Surgical Endoscopy 2017, 31(7):2946-2952.

Kobborg M, Broholm M, Frostberg E, Jeppesen M, Gögenür I: Short‐term results of self‐expanding metal stents for acute malignant large bowel obstruction. Colorectal Disease 2017, 19(10):O365-O371.

Baron TH: Interventional palliative strategies for malignant bowel obstruction. Current Oncology Reports 2009, 11(4):293-297.

Brooksbank M, Game P, Ashby M: Palliative venting gastrostomy in malignant intestinal obstruction. Palliative medicine 2002, 16(6):520-526.

Diver E, O'Connor O, Garrett L, Boruta D, Goodman A, Del Carmen M, Schorge J, Mueller P, Growdon W: Modest benefit of total parenteral nutrition and chemotherapy after venting gastrostomy tube placement. Gynecologic oncology 2013, 129(2):332-335.

Richards DM, Tanikella R, Arora G, Guha S, Dekovich AA: Percutaneous endoscopic gastrostomy in cancer patients: predictors of 30-day complications, 30-day mortality, and overall mortality. Digestive diseases and sciences 2013, 58:768-776.

Hodge C, Badgwell BD: Palliation of malignant ascites. Journal of surgical oncology 2019, 120(1):67-73.

Kefala G, Papamichael D: Malignant Ascites. ESMO Handbooks: Supportive and Palliative Care European Society for Medical Oncology 2022:98-99.

Smith E, Jayson GC: The current and future management of malignant ascites. Clinical oncology 2003, 15(2):59-72.

Fukui H, Kawaratani H, Kaji K, Takaya H, Yoshiji H: Management of refractory cirrhotic ascites: challenges and solutions. Hepatic medicine: evidence and research 2018:55-71.

Jatoi A, Nieva JJ, Qin R, Loprinzi CL, Wos EJ, Novotny PJ, Moore J, Dennis F, Mowat RB, Bechar N, Pajon J, Eduardo R: A pilot study of long-acting octreotide for symptomatic malignant ascites. Oncology 2012, 82(6):315-320.

Peterson D, Bensadoun R-J, Roila F: Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Annals of oncology 2011, 22:vi78-vi84.

Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber‐Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE: Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer: Interdisciplinary International Journal of the American Cancer Society 2007, 109(5):820-831.

Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, McGuire DB, Migliorati C, Nicolatou‐Galitis O, Peterson DE: MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2014, 120(10):1453-1461.

Boers-Doets CB, Raber-Durlacher JE, Treister NS, Epstein JB, Arends AB, Wiersma DR, Lalla RV, Logan RM, Van Erp NP, Gelderblom H: Mammalian target of rapamycin inhibitor-associated stomatitis. Future oncology 2013, 9(12):1883-1892.

National Cancer Institute PDQ®. Oral mucositis. In Oral Complications of Chemotherapy/Head & Neck Radiation; http://www.cancer.gov/cancertopics/pdq/ supportivecare/oralcomplications/HealthProfessional/page5 (21 October 2024, date last accessed).

Sonis S, Treister N, Chawla S, Demetri G, Haluska F: Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer: Interdisciplinary International Journal of the American Cancer Society 2010, 116(1):210-215.

Watters A, Epstein J, Agulnik M: Oral complications of targeted cancer therapies: a narrative literature review. Oral oncology 2011, 47(6):441-448.

Li E, Trovato JA: New developments in management of oral mucositis in patients with head and neck cancer or receiving targeted anticancer therapies. American Journal of Health-System Pharmacy 2012, 69(12):1031-1037.

Pilotte AP, Hohos MB, Polson KM, Huftalen TM, Treister N: Managing stomatitis in patients treated with Mammalian target of rapamycin inhibitors. Clinical journal of oncology nursing 2011, 15(5).

De Oliveira MA, e Martins FM, Wang Q, Sonis S, Demetri G, George S, Butrynski J, Treister NS: Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral oncology 2011, 47(10):998-1003.

Peterson D, Boers-Doets C, Bensadoun R, Herrstedt J: Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Annals of Oncology 2015, 26:v139-v151.

Elting LS, Chang Y-C, Parelkar P, Boers-Doets CB, Michelet M, Hita G, Rouleau T, Cooksley C, Halm J, Vithala M: Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. Supportive Care in Cancer 2013, 21:3243-3254.

Kwitkowski VE, Prowell TM, Ibrahim A, Farrell AT, Justice R, Mitchell SS, Sridhara R, Pazdur R: FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. The oncologist 2010, 15(4):428-435.

Keefe D, Stringer A: The potential successes and challenges of targeted anticancer therapies. Current opinion in supportive and palliative care 2010, 4(1):16-18.

Lewis SJ, Heaton KW: Stool form scale as a useful guide to intestinal transit time. Scandinavian journal of gastroenterology 1997, 32(9):920-924.

McGuire DB, Fulton JS, Park J, Brown CG, Correa MEP, Eilers J, Elad S, Gibson F, Oberle-Edwards LK, Bowen J: Systematic review of basic oral care for the management of oral mucositis in cancer patients. Supportive Care in Cancer 2013, 21:3165-3177.

Eilers Jr R, Gandhi M, Patel J, Mulcahy M, Agulnik M, Hensing T, Lacouture ME: Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. Journal of the National Cancer Institute 2010, 102(1):47-53.

Duvic M: EGFR inhibitor-associated acneiform folliculitis: assessment and management. American Journal of Clinical Dermatology 2008, 9:285-294.

Amitay-Laish I, David M, Stemmer SM: Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions. The oncologist 2010, 15(9):1002-1008.

Kajiya K, Sawane M, Huggenberger R, Detmar M: Activation of the VEGFR-3 pathway by VEGF-C attenuates UVB-induced edema formation and skin inflammation by promoting lymphangiogenesis. Journal of Investigative Dermatology 2009, 129(5):1292-1298.

Roigas J: Clinical management of patients receiving tyrosine kinase inhibitors for advanced renal cell carcinoma. european urology supplements 2008, 7(9):593-600.

Venkatesh GH, Manjunath VB, Mumbrekar KD, Negi H, Fernandes DJ, Sharan K, Banerjee S, Bola Sadashiva SR: Polymorphisms in radio-responsive genes and its association with acute toxicity among head and neck cancer patients. PloS one 2014, 9(3):e89079.

Sonis S, Antin J, Tedaldi M, Alterovitz G: SNP‐based B ayesian networks can predict oral mucositis risk in autologous stem cell transplant recipients. Oral diseases 2013, 19(7):721-727.

Peterson DE, Keefe DM, Sonis ST: New frontiers in mucositis. American Society of Clinical Oncology Educational Book 2012, 32(1):545-551.

Jensen SB, Peterson DE: Oral mucosal injury caused by cancer therapies: current management and new frontiers in research. Journal of Oral Pathology & Medicine 2014, 43(2):81-90.

Strojan P, Hutcheson KA, Eisbruch A, Beitler JJ, Langendijk JA, Lee AW, Corry J, Mendenhall WM, Smee R, Rinaldo A: Treatment of late sequelae after radiotherapy for head and neck cancer. Cancer treatment reviews 2017, 59:79-92.

Riley P, Glenny AM, Hua F, Worthington HV, Group COH: Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy. Cochrane Database of Systematic Reviews 1996, 2017(7).

Health NIo: Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Published: November 27, 2017. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. National Institutes of Health https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf (Accessed on April 03, 2023). 2017.

Jd C: Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 1995, 31:1341-1346.

Jensen K, Jensen AB, Grau C: The relationship between observer-based toxicity scoring and patient assessed symptom severity after treatment for head and neck cancer. A correlative cross sectional study of the DAHANCA toxicity scoring system and the EORTC quality of life questionnaires. Radiotherapy and Oncology 2006, 78(3):298-305.

Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay M: Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. The lancet oncology 2011, 12(2):127-136.

Brouwer CL, Steenbakkers RJ, Bourhis J, Budach W, Grau C, Grégoire V, Van Herk M, Lee A, Maingon P, Nutting C: CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines. Radiotherapy and Oncology 2015, 117(1):83-90.

Deasy JO, Moiseenko V, Marks L, Chao KC, Nam J, Eisbruch A: Radiotherapy dose–volume effects on salivary gland function. International Journal of Radiation Oncology* Biology* Physics 2010, 76(3):S58-S63.

Wang X, Eisbruch A: IMRT for head and neck cancer: reducing xerostomia and dysphagia. Journal of radiation research 2016, 57(S1):i69-i75.

Vigarios E, Epstein JB, Sibaud V: Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Supportive Care in Cancer 2017, 25:1713-1739.

Wolff A, Joshi RK, Ekström J, Aframian D, Pedersen AML, Proctor G, Narayana N, Villa A, Sia YW, Aliko A: A guide to medications inducing salivary gland dysfunction, xerostomia, and subjective sialorrhea: a systematic review sponsored by the world workshop on oral medicine VI. Drugs in R&d 2017, 17:1-28.

Yang W-f, Liao G-q, Hakim SG, Ouyang D-q, Ringash J, Su Y-x: Is pilocarpine effective in preventing radiation-induced xerostomia? A systematic review and meta-analysis. International Journal of Radiation Oncology* Biology* Physics 2016, 94(3):503-511.

Jensen SB, Pedersen AML, Vissink A, Andersen E, Brown C, Davies A, Dutilh J, Fulton J, Jankovic L, Lopes N: A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact. Supportive care in cancer 2010, 18:1061-1079.

Mercadante V, Al Hamad A, Lodi G, Porter S, Fedele S: Interventions for the management of radiotherapy-induced xerostomia and hyposalivation: A systematic review and meta-analysis. Oral oncology 2017, 66:64-74.

Fox NF, Xiao C, Sood AJ, Lovelace TL, Nguyen SA, Sharma A, Day TA: Hyperbaric oxygen therapy for the treatment of radiation-induced xerostomia: a systematic review. Oral surgery, oral medicine, oral pathology and oral radiology 2015, 120(1):22-28.

Johnstone C, Rich SE: Bleeding in cancer patients and its treatment: a review. Annals of palliative medicine 2018, 7(2):26573-26273.

Talley NA, Chen F, King D, Jones M, Talley NJ: Short-chain fatty acids in the treatment of radiation proctitis: a randomized, double-blind, placebo-controlled, cross-over pilot trial. Diseases of the colon & rectum 1997, 40:1046-1050.

Èavèiæ J, Turèiæ J, Martinac P, Županèiæ B, Panijan-Pezeroviæ R, Unušiæ J: Metronidazole in the treatment of chronic radiation proctitis: clinical trial. Croat Med J 2000, 4:314-318.

Ehrenpreis ED, Jani A, Levitsky J, Ahn J, Hong J: A prospective, randomized, double-blind, placebo-controlled trial of retinol palmitate (vitamin A) for symptomatic chronic radiation proctopathy. Diseases of the colon & rectum 2005, 48:1-8.

Clarke RE, Tenorio LC, Hussey JR, Toklu AS, Cone DL, Hinojosa JG, Desai SP, Parra LD, Rodrigues SD, Long RJ: Hyperbaric oxygen treatment of chronic refractory radiation proctitis: a randomized and controlled double-blind crossover trial with long-term follow-up. International Journal of Radiation Oncology* Biology* Physics 2008, 72(1):134-143. e115.

Fearon K, Arends J, Baracos V: Understanding the mechanisms and treatment options in cancer cachexia. Nature reviews Clinical oncology 2013, 10(2):90-99.

Schcolnik-Cabrera A, Chávez-Blanco A, Domínguez-Gómez G, Dueñas-González A: Understanding tumor anabolism and patient catabolism in cancer-associated cachexia. American journal of cancer research 2017, 7(5):1107.

Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G: Definition and classification of cancer cachexia: an international consensus. The lancet oncology 2011, 12(5):489-495.

Bokhorst-de van der Schueren Mv, Guaitoli PR, Jansma EP, Vet Hd: Nutrition screening tools: does one size fit all? A systematic review of screening tools for the hospital setting. 2014.

Arends J: Nutrition in Cancer Patients. Aktuelle Ernährungsmedizin 2012, 37(02):91-106.

Arends J, Strasser F, Gonella S, Solheim TS, Madeddu C, Ravasco P, Buonaccorso L, De Van Der Schueren M, Baldwin C, Chasen M: Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆. ESMO open 2021, 6(3):100092.

Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, Fearon K, Hütterer E, Isenring E, Kaasa S: ESPEN guidelines on nutrition in cancer patients. Clinical nutrition 2017, 36(1):11-48.

Garcia VR, López‐Briz E, Sanchis RC, Perales JLG, Bort‐Martí S: Megestrol acetate for treatment of anorexia‐cachexia syndrome. Cochrane Database of Systematic Reviews 2013(3).

Dev R, Del Fabbro E, Bruera E: Association between megestrol acetate treatment and symptomatic adrenal insufficiency with hypogonadism in male patients with cancer. Cancer 2007, 110(6):1173-1177.

Solheim TS, Fearon KC, Blum D, Kaasa S: Non-steroidal anti-inflammatory treatment in cancer cachexia: a systematic literature review. Acta Oncologica 2013, 52(1):6-17.

Oberholzer R, Hopkinson JB, Baumann K, Omlin A, Kaasa S, Fearon KC, Strasser F: Psychosocial effects of cancer cachexia: a systematic literature search and qualitative analysis. Journal of pain and symptom management 2013, 46(1):77-95.

Orrevall Y, Tishelman C, Herrington MK, Permert J: The path from oral nutrition to home parenteral nutrition: a qualitative interview study of the experiences of advanced cancer patients and their families. Clinical nutrition 2004, 23(6):1280-1287.

Strasser F, Binswanger J, Cerny T, Kesselring A: Fighting a losing battle: eating-related distress of men with advanced cancer and their female partners. A mixed-methods study. Palliative Medicine 2007, 21(2):129-137.

Reid J, McKenna H, Fitzsimons D, McCance T: The experience of cancer cachexia: a qualitative study of advanced cancer patients and their family members. International journal of nursing studies 2009, 46(5):606-616.

Hopkinson JB, Fenlon DR, Okamoto I, Wright DN, Scott I, Addington-Hall JM, Foster C: The deliverability, acceptability, and perceived effect of the Macmillan approach to weight loss and eating difficulties: a phase II, cluster-randomized, exploratory trial of a psychosocial intervention for weight-and eating-related distress in people with advanced cancer. Journal of pain and symptom management 2010, 40(5):684-695.

Hopkinson JB, Richardson A: A mixed-methods qualitative research study to develop a complex intervention for weight loss and anorexia in advanced cancer: the family approach to weight and eating. Palliative medicine 2015, 29(2):164-176.

Millar C, Reid J, Porter S: Healthcare professionals' response to cachexia in advanced cancer: a qualitative study. In: Oncology nursing forum: 2013; 2013.

Amano K, Maeda I, Morita T, Okajima Y, Hama T, Aoyama M, Kizawa Y, Tsuneto S, Shima Y, Miyashita M: Eating‐related distress and need for nutritional support of families of advanced cancer patients: a nationwide survey of bereaved family members. Journal of cachexia, sarcopenia and muscle 2016, 7(5):527-534.